Serine proteinases, such as trypsin and chymotrypsin, are proteolytic enzymes that have been used therapeutically to support wound healing, including abrasions. Their primary mechanism involves the enzymatic debridement of necrotic tissue and the reduction of local inflammation. By breaking down damaged proteins and fibrin, serine proteinases can help clear wound debris, which may facilitate the natural healing process and reduce the risk of infection. Several studies, including randomized controlled trials and observational clinical reports, have investigated topical or systemic use of serine proteinases in wound management. These studies generally report accelerated wound cleaning and, in some cases, faster healing times compared to standard care or placebo. However, the evidence is mixed, with some trials finding minimal or no significant benefit. The quality of available studies varies, with limitations including small sample sizes and heterogeneity in study design.

Notably, serine proteinases are included in some topical formulations and medical devices for wound care, reflecting their acceptance in clinical practice. International wound care guidelines acknowledge enzymatic debridement as a useful adjunct in selected cases, although they do not specifically recommend serine proteinases over other debriding agents. Overall, while serine proteinases have a plausible biological rationale and some clinical data to support their use in the management of abrasions, the strength of evidence is moderate (rated 3/5). Further well-designed, large-scale studies are needed to confirm their efficacy and to better define their role in wound care protocols.